How ARALAST Works

• Considering Alpha-1 Testing
• Newly Diagnosed with Alpha-1
• Living With Alpha-1

eLearning Program

View our eLearning Program to learn more about Alpha-1

 

Alpha1Health.com Survey

Take our survey to help us best meet the needs of the Alpha-1 community.

 

View See How ARALAST Works Animation

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is an augmentation therapy which works by increasing the levels of alpha-1 antitrypsin (AAT) in your blood and lungs.

If you have AAT deficiency, your body does not produce enough A₁-PI. Having the right amount of A₁-PI, also called alpha-1 antitrypsin (AAT), is important to protect your lungs from damage caused by neutrophil elastase (NE), an enzyme released by white blood cells. To learn more about the important role AAT plays in protecting your lungs, read About Alpha-1.

ARALAST is administered by intravenous infusion once a week. With augmentation therapy, blood levels of A₁-PI rise to levels exceeding the "protective threshold," as recommended by the American Thoracic Society and European Respiratory Society.¹

It is important to understand that ARALAST augmentation therapy is not a cure for AAT deficiency. It cannot repair damage that has already occurred in your lungs. However, augmentation therapy with ARALAST may slow further progression of lung disease.

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information